Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $3.58M rose 10.3% year over year, behind the +64.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 20.7% from the prior quarter. Over 3 fiscal years it compounded at +21.7% a year.

Context

  • Stock-based compensation amounted to 23086.4% of revenue in FY2025, up 21759.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.3% toward the trailing-twelve-month pace of +64.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.58M-20.7% QoQ
Last fiscal yearDec 2025
$13.62M+132.8% YoY
LTMMar 2026
$13.96M+64.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.3%——
1 year+132.8%——
3-year CAGR+21.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
13.62M USD
Year-over-year change
+132.8%
4-year CAGR
+13.6%

Stock-Based Compensation vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +64.9% is the highest of 9, against a peer median of +4.1%.
  • Stock-based compensation amounts to 23652.5% of revenue for AVTX, versus a peer median of 46.4%.
AVTX Competitors
Stock-Based Compensation for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$50.3M USD+35.9%+74.2%55.6%
ANABAnaptysBio, Inc.LTM Mar 2026$41.12M USD+24.3%+9.7%17.7%
XNCRXencor, Inc.LTM Jun 2026$39.03M USD+10.2%-4.0%37.2%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M USD-2.1%-6.3%144.0%
IMUXImmunic, Inc.LTM Mar 2026$11.29M USD+44.4%+3.8%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$9.79M USD-31.5%+8.6%—
QTTBQ32 Bio Inc.LTM Mar 2026$3.99M USD-24.8%+61.9%7.4%
IFRXInflaRx N.V.LTM Mar 2026€2.48M EUR-152.9%—8455.2%
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding AVTX) —+4.1%+8.6%46.4%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Depreciation & Amortization1.66M166K158K169K344K
Deferred Income Tax22K28K14K114K165K
Stock-Based Compensation8.17M7.55M3.48M5.85M13.62M
Change in Working Capital2.84M(60K)(9.24M)(4.71M)3.84M
Accounts Receivables1.12M2.88M1.78M(475K)0
Inventory(35K)18K20K00
Accounts Payables796K(487K)(2.44M)(163K)(146K)
Other Working Capital961K(2.47M)(8.61M)(4.07M)3.99M
Other Non-Cash Items794K7.22M6.46M(15.35M)8.83M
Operating Cash Flow(70.89M)(26.75M)(30.68M)(49.06M)(51.46M)
Capital Expenditures(113K)(95K)(158K)00
Acquisitions (Net)000356K0
Purchases of Investments0000(113.72M)
Sales of Investments000031.31M
Other Investing Activities0025K0690K
Investing Cash Flow(113K)(95K)(133K)356K(81.72M)
Debt Repayment32.9M(14.81M)(21.24M)00
Common Stock Issued71.93M107K46.22M115.63M15.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.93M067K60.22M(510K)
Financing Cash Flow106.76M(14.7M)25.04M175.85M14.59M
Effect of Forex Changes096K000
Net Change in Cash35.76M(41.45M)(5.77M)127.15M(118.59M)
Free Cash Flow(71.01M)(26.85M)(30.84M)(49.06M)(51.46M)

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.